Roche’s Polivy Reverts To Standard Review In EU
US-approved r/r DLBCL treatment has lost its accelerated assessment status
Just two products are being assessed under the EMA's fast-track mechanism now that the marketing application for Roche's Polivy has reverted to standard review.
